Nath Bio-Genes (India) Limited announced the outcome of its Board Meeting held on Saturday, 31st January 2026. The Board approved the standalone and consolidated unaudited financial results for the quarter and nine months ended 31st December 2025. For the quarter ended 31st December 2025, the standalone net profit after tax stood at ₹723.08 lakh (₹7.23 crore), a significant increase from ₹420.09 lakh (₹4.20 crore) in the same quarter last year. Revenue from operations for the standalone entity was ₹6596.11 lakh (₹65.96 crore). The consolidated unaudited financial results for the quarter ended 31st December 2025 reported a net profit after tax of ₹160.49 lakh (₹1.60 crore), a decrease from ₹481.67 lakh (₹4.81 crore) in the corresponding quarter of the previous year. Consolidated revenue from operations was ₹6595.90 lakh (₹65.96 crore). For the nine months ended 31st December 2025, standalone net profit after tax was ₹4463.77 lakh (₹44.64 crore), while consolidated net profit after tax was ₹4163.92 lakh (₹41.64 crore). The company also noted that the financial results were reviewed by the Audit Committee on 30 January 2026, prior to the Board's approval. Investor complaints received and pending at the end of the quarter were nil. The company's website, www.nathbiogenes.com, will host the information.
